What is the difference between printing a skin graft versus printing a regenerative patch like that of ROKIT Healthcare’s DFU platform?
Printing a skin graft would require culturing, whether the cells are from the patient or another donor. Such a process of culturing categorizes this treatment as a cell therapy and therefore is likely to take time until market commercialization. ROKIT Healthcare’s choice of printing a regenerative patch rather than a fully mature graft comes from our commitment to accelerate the commercialization of the bioprinting-based therapy within a short time in the operating theater. It also comes from our trust in the evidence collected in our clinical studies that demonstrate having autologous solutions directly printed in customized shape to wounds have strong enough regenerative potential already.